{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-036792","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2026-02-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.367085+00:00","generated_at":"2026-05-16T04:45:51.463066+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sangamo raises ~$25M in underwritten offering of common stock and warrants; amends prior warrants","bullets":["Offering of 35.19M shares + pre-funded warrants for 17.79M shares, each with a purchase warrant for 52.98M shares.","Combined price per share+ warrant is $0.4719; pre-funded warrant+ warrant at $0.4619; gross proceeds ~$25M.","Existing warrants held by investor repriced from $1.00 to $0.4719 and expiration extended to 5.5 years from closing.","Closing expected February 4, 2026; proceeds for general corporate purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-036792","json":"https://secwatch.observer/filing/0001193125-26-036792.json","markdown":"https://secwatch.observer/filing/0001193125-26-036792.md","text":"https://secwatch.observer/filing/0001193125-26-036792.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000119312526036792/0001193125-26-036792-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000119312526036792/d101629d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T04:45:51.463066+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"212ef34b201190a7c0350fa3336f23c35158e02e","claim":"SANGAMO THERAPEUTICS, INC entered into Underwriting Agreement with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC valued at approximately $25.0 million (effective 2026-02-03).","evidence_excerpt":"On February 3, 2026, Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1001233/000119312526036792/0001193125-26-036792-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC"},{"label":"Value","value":"approximately $25.0 million"},{"label":"Effective","value":"2026-02-03"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}